Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

 
• By Dean Rudge
  
rebate - cube with letters, sign with wooden cubes
Sandoz continues to wait for a CMS decision on whether two of its products should be classified as innovator drugs. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Generics

More from Biosimilars & Generics